1. OC-048 Filgotinib, a selective jak1 inhibitor, induces clinical remission and a reduction in pstat3 levels in patients with active crohn's disease: results from the phase ii fitzroy study. (17th June 2017) Authors: Keshav, S; Goh, J; Hart, A; Levison, S; McLaughlin, S; der, Avan Aa; Galien, R; Pan, Y; Meuleners, L; Jamoul, C; Tasset, C; Harrison, P; Vermeire, S Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗